Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (S)-Pia SCHEMBL2506660 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3TP53CYP3A4 | |
| (S)-Pia SCHEMBL25566839 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3TP53CYP3A4 | |
| (R)-Pia SCHEMBL29389146 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3TP53CYP3A4 | |
| (S)-Pia SCHEMBL25566844 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3TP53CYP3A4 | |
| (S)-Pia SCHEMBL25566838 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3TP53CYP3A4 | |
| (R)-Pia SCHEMBL8907369 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3TP53CYP3A4 | |
| (S)-Pia SCHEMBL14829806 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3TP53CYP3A4 | |
| (S)-Pia SCHEMBL6762494 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3TP53CYP3A4 | |
| (S)-Pia SCHEMBL29616978 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA3TP53CYP3A4 | |
| SCHEMBL10601202 | 0.92 | ADORA2A (0.85) | ADORA2AADORA2BADORA3TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017137528-A1 | ADENOSINE A1 RECEPTOR AGONIST FOR USE IN TREATMENT OF STATUS EPILEPTICUS | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2017-08-17 | — | — | WO | claimed |
| EP-0996453-B1 | METHODS FOR THE INHIBITION OF NEURONAL ACTIVITY BY LOCAL DELIVERY OF ADENOSINE | MOHLER HANNS (CH) | 2004-04-28 | — | — | EP | claimed |
| US-12606564-B2 | Adenosine receptor antagonist compounds | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2026-04-21 | — | — | US | disclosed |
| EP-4471790-B1 | SYSTEM AND METHOD FOR DETERMINING MICROBIOME FROM HOST METABOLOME USING A MACHINE LEARNING MODEL | MICROBIOTX HEALTH PRIVATE LTD (IN) | 2026-04-01 | — | — | EP | disclosed |
| EP-4471790-A1 | SYSTEM AND METHOD FOR DETERMINING MICROBIOME FROM HOST METABOLOME USING A MACHINE LEARNING MODEL | MicrobioTx Health Private Limited (IN) | 2024-12-04 | — | — | EP | disclosed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| US-20240041888-A1 | PREVENTION AND/OR TREATMENT OF CNS DISORDERS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2024-02-08 | — | — | US | disclosed |
| US-11806350-B2 | Prevention and/or treatment of CNS disorders | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-07 | — | — | US | disclosed |
| CN-116425756-A | Adenosine receptor antagonist compounds and uses thereof | 日东制药株式会社 | 2023-07-14 | — | — | CN | disclosed |
| US-5683989-A | TREATMENT OF CARDIOVASCULAR AND NERVOUS SYSTEM DISORDERS | NOVO NORDISK A/S (DK) | 1997-11-04 | — | — | US | disclosed |
| US-5672588-A | Purine derivatives | NOVO NORDISK A/S (DK) | 1997-09-30 | — | — | US | disclosed |
| EP-0652884-B1 | PHOSPHONATED ARYLETHANOLAMINE COMPOUNDS WITH ANTI-HYPERGLYCEMIC AND/OR ANTI-OBESITY ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1997-05-28 | — | — | EP | disclosed |
| US-5589467-A | TREATING CENTRAL NERVOUS SYSTEM DISORDERS | NOVO NORDISK A/S (DK) | 1996-12-31 | — | — | US | disclosed |
| US-5578582-A | Methods of treating ischemia with C2, N6 -disubstituted adenosine derivatives | NOVO NORDISK A/S (DK) | 1996-11-26 | — | — | US | disclosed |
| US-5484774-A | 2, N6 -disubstituted adenosines, tri-O-ester derivatives and their pharmaceutical compositions to treat ischemias | NOVO NORDISK A/S (DK) | 1996-01-16 | — | — | US | disclosed |
| US-5432164-A | Anticonvulsants | NOVO NORDISK A/S (DK) | 1995-07-11 | — | — | US | disclosed |
| EP-0603348-A1 | PURINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1994-06-29 | — | — | EP | disclosed |
| WO-1993023418-A1 | PURINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041888-A1 | PREVENTION AND/OR TREATMENT OF CNS DISORDERS | ADORA2A, ADORA1, ADORA2B | ADORA2A 1/4885ADORA2B 3/4885ADORA3 4/4885 |
| US-12606564-B2 | Adenosine receptor antagonist compounds | ADORA2A, ADORA1, ADORA2B | ADORA2A 1/4885ADORA2B 3/4885ADORA3 4/4885 |
| US-11806350-B2 | Prevention and/or treatment of CNS disorders | ADORA2A, ADORA1, ADORA2B | ADORA2A 1/4885ADORA2B 3/4885ADORA3 4/4885 |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | ADORA2A 2398/4885ADORA2B 1646/4885ADORA3 2478/4885 |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | ADORA2A 24/4885ADORA2B 35/4885ADORA3 84/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | ADORA2A 24/4885ADORA2B 35/4885ADORA3 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.